9amHealth raises $26M to tackle chronic care costs for employers
What's the deal? 9amHealth, a virtual care startup, has raised $26M to expand its AI-driven platform beyond cardiometabolic conditions into the broader set of chronic diseases that drive the majority of employer pharmacy spend.
The company initially focused on diabetes and related metabolic conditions but is now widening its scope to address a larger share of the chronic care burden employers face.
Why now? Employer pharmacy costs are surging, driven largely by chronic conditions like diabetes, heart disease, and obesity. As GLP-1 drugs and other specialty medications push spend higher, employers are looking for virtual care platforms that can manage costs while improving outcomes.
AI-powered care models have matured enough to handle multi-condition management at scale, giving companies like 9amHealth the tools to expand beyond a single disease focus.
What could go wrong? The virtual chronic care market is crowded. Companies like Virta Health, Omada Health, and Livongo (now part of Teladoc) already target overlapping populations. Differentiating on outcomes and cost savings — and proving it to sceptical benefits teams — remains a challenge.
Expanding into new condition areas also means building or buying clinical expertise fast, which can strain operations and dilute the quality that won investors in the first place.
The signal: This raise reflects a broader shift in employer health benefits: instead of point solutions for individual conditions, buyers want consolidated platforms that manage multiple chronic diseases under one roof. The economics of pharmacy spend are forcing the issue — and startups that can bundle AI triage, care coordination, and medication management stand to capture a growing share of that budget.
Read more: prnewswire.com
